TScan Therapeutics, Inc. (TCRX)
- Previous Close
8.41 - Open
8.54 - Bid 8.71 x 200
- Ask 8.77 x 400
- Day's Range
8.33 - 8.80 - 52 Week Range
1.93 - 9.69 - Volume
260,263 - Avg. Volume
206,080 - Market Cap (intraday)
462.021M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-0.78 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.57
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
www.tscan.comRecent News: TCRX
Performance Overview: TCRX
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCRX
Valuation Measures
Market Cap
462.02M
Enterprise Value
391.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.27
Price/Book (mrq)
3.62
Enterprise Value/Revenue
25.22
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.79%
Return on Equity (ttm)
-71.29%
Revenue (ttm)
21.05M
Net Income Avi to Common (ttm)
-89.22M
Diluted EPS (ttm)
-0.78
Balance Sheet and Cash Flow
Total Cash (mrq)
192.04M
Total Debt/Equity (mrq)
61.27%
Levered Free Cash Flow (ttm)
-41.83M